Cost-effectiveness analysis of rituximab versus natalizumab in patients with relapsing remitting multiple sclerosis

Mehdi Rezaee, Mohammad Hossein Morowvat, Maryam Poursadeghfard, Armin Radgoudarzi, Khosro Keshavarz

Open source

DOI: 10.1186/s12913-022-07495-4
Published: 2022-01-28
Container: BMC Health Services Research
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1186/s12913-022-07495-4,
  title = {Cost-effectiveness analysis of rituximab versus natalizumab in patients with relapsing remitting multiple sclerosis},
  author = {Mehdi Rezaee and Mohammad Hossein Morowvat and Maryam Poursadeghfard and Armin Radgoudarzi and Khosro Keshavarz},
  year = {2022},
  journal = {BMC Health Services Research},
  doi = {10.1186/s12913-022-07495-4},
  url = {https://doi.org/10.1186/s12913-022-07495-4}
}

RIS

TY  - JOUR
TI  - Cost-effectiveness analysis of rituximab versus natalizumab in patients with relapsing remitting multiple sclerosis
AU  - Mehdi Rezaee
AU  - Mohammad Hossein Morowvat
AU  - Maryam Poursadeghfard
AU  - Armin Radgoudarzi
AU  - Khosro Keshavarz
PY  - 2022
JO  - BMC Health Services Research
DO  - 10.1186/s12913-022-07495-4
UR  - https://doi.org/10.1186/s12913-022-07495-4
ER  -

APA

Rezaee, M., Morowvat, M. H., Poursadeghfard, M., Radgoudarzi, A., & Keshavarz, K. (2022). Cost-effectiveness analysis of rituximab versus natalizumab in patients with relapsing remitting multiple sclerosis. BMC Health Services Research. https://doi.org/10.1186/s12913-022-07495-4

Source records

crossref · retrieved 2026-09-27T15:35:21.481Z